Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
๏ปฟ

NDAQ:MNMD - Post by User

Post by GajjarDron Apr 29, 2021 12:50pm
587 Views
Post# 33094066

Valuation::: Easy $10 ๐Ÿ‘‰๐“‹ผ๐Ÿค‘๐“‹ผ๐Ÿ‘ˆ Canopy of Mushroom Space!!

Valuation::: Easy $10 ๐Ÿ‘‰๐“‹ผ๐Ÿค‘๐“‹ผ๐Ÿ‘ˆ Canopy of Mushroom Space!!

Next-Gen Psychedelic Innovation

MindMed is discovering and researching a broad range of novel compounds, therapies, and technologies with the goal of unlocking new pathways for patients. 

Technologies and analytics that seek to personalize psychedelic therapy experiences for a specific patient are imperative to the patient experience. This technology aims to optimize the dosing of MDMA, LSD and other psychedelics based on a patient’s profile. The R&D is taking place in collaboration with the University Hospital Basel’s Liechti Lab, the leading research center focused on the pharmacology of psychedelic substances.
<< Previous
Bullboard Posts
Next >>